Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Cash from Operations: 2017-2025

Historic Cash from Operations for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to -$10.9 million.

  • Aclaris Therapeutics' Cash from Operations fell 149.69% to -$10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.9 million, marking a year-over-year decrease of 139.80%. This contributed to the annual value of -$20.1 million for FY2024, which is 74.37% up from last year.
  • Per Aclaris Therapeutics' latest filing, its Cash from Operations stood at -$10.9 million for Q3 2025, which was down 9.40% from -$10.0 million recorded in Q2 2025.
  • Aclaris Therapeutics' 5-year Cash from Operations high stood at $22.0 million for Q3 2024, and its period low was -$26.4 million during Q1 2023.
  • Moreover, its 3-year median value for Cash from Operations was -$12.3 million (2024), whereas its average is -$12.0 million.
  • Per our database at Business Quant, Aclaris Therapeutics' Cash from Operations crashed by 214.15% in 2023 and then skyrocketed by 189.59% in 2024.
  • Quarterly analysis of 5 years shows Aclaris Therapeutics' Cash from Operations stood at -$17.1 million in 2021, then decreased by 11.95% to -$19.1 million in 2022, then surged by 64.63% to -$6.8 million in 2023, then plummeted by 32.20% to -$8.9 million in 2024, then slumped by 149.69% to -$10.9 million in 2025.
  • Its Cash from Operations stands at -$10.9 million for Q3 2025, versus -$10.0 million for Q2 2025 and -$13.1 million for Q1 2025.